secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001654954-24-007727
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics expands equity pool by 400k shares; CMO shifts to part-time
------------------------------------------------------------------------------

- Stockholders approved Amendment No. 1 to 2022 Stock Incentive Plan, increasing authorized shares to 400,688.
- CMO Dr. Stuart Rich will work 3 days/week from June 15, 2024; annual base salary of $333,900 prorated to 60%.
- Board elected; auditor Cherry Bekaert LLP ratified. Next advisory vote on exec compensation set for 2025 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424007727/0001654954-24-007727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424007727/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-007727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer